CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

Employees - 191, CEO - Joseph Todisco, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 2.12, Piotroski Score(max is 10): 4, Working Capital: $293158000, Total Assets: $904052000, Retained Earnings: $-111986000, EBIT: 214519935, Total Liabilities: $443219000, Revenue: $462248553

- Current Price $ - Analyst Target Price $